Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
Sweden flag Sweden · Delayed Price · Currency is SEK
2.600
-0.020 (-0.76%)
Jul 25, 2025, 5:29 PM CET

STO:NEWBRY Income Statement

Millions SEK. Fiscal year is Sep - Aug.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
May '25 Aug '24 Aug '23 Aug '22 Aug '21
46.7836.8310.275.523.09
Revenue Growth (YoY)
152.42%258.75%86.11%78.73%-
Cost of Revenue
24.7420.86.323.952.58
Gross Profit
22.0416.033.951.560.5
Selling, General & Admin
30.1528.7720.8114.665.95
Other Operating Expenses
0.33---0.12-0.01
Operating Expenses
32.3930.522.0715.556.6
Operating Income
-10.36-14.47-18.12-13.99-6.1
Interest Expense
-1.82-1.53---0.04
Interest & Investment Income
0.20.20.16-0.11
Currency Exchange Gain (Loss)
0.390.39-1.47-0.68-0.03
Pretax Income
-11.56-15.41-19.43-14.67-6.06
Income Tax Expense
-0.23-0---
Net Income
-11.33-15.41-19.43-14.67-6.06
Net Income to Common
-11.33-15.41-19.43-14.67-6.06
Shares Outstanding (Basic)
24212018-
Shares Outstanding (Diluted)
24212018-
Shares Change (YoY)
20.74%9.68%9.68%--
EPS (Basic)
-0.46-0.72-1.00-0.82-
EPS (Diluted)
-0.46-0.72-1.00-0.82-
Gross Margin
47.11%43.53%38.46%28.35%16.26%
Operating Margin
-22.13%-39.29%-176.51%-253.57%-197.67%
Profit Margin
-24.22%-41.83%-189.28%-265.90%-196.43%
EBITDA
-9.35-13.65-17.78-13.89-
EBITDA Margin
-19.99%-37.05%-173.17%-251.87%-
D&A For EBITDA
10.820.340.09-
EBIT
-10.36-14.47-18.12-13.99-6.1
EBIT Margin
-22.13%-39.29%-176.51%-253.57%-197.67%
Revenue as Reported
39.7439.7411.177.243.1
Source: S&P Global Market Intelligence. Standard template. Financial Sources.